Close menu




• Adocia’s partner, Tonghua Dongbao, announced that the primary endpoint of this Phase 1 study was reached, and the results confirmed the accelerated profile of BioChaperone Lispro in comparison to lispro.

• Ongoing Phase 3 studies are the only remaining clinical activities planned before submittingthe marketing authorization file to the Chinese Regulatory Authorities.

• BioChaperone Lispro is expected to be the first analog of Ultra-Rapid Insulin to be marketed in China by a Chinese company.



Read the press release

More information